Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.

Signal Transduct Target Ther · 2024 · PMC11625825 · PMID 39648226

Europe PMC DOI

hedged sentence

0.2100

closest p · 4.2× alpha

0.2100

boldest claim

The sentences

did not reach statistical significanceP = 0.210not close (p > 0.1)

Our analysis of OS also found a more favorable trend in HER2-low MBC patients with MRG mutations compared to HER2-0 MBC, although this difference did not reach statistical significance (median OS: 61.2 months vs 34.2 months, P = 0.210, Supplementary Table 4 and Fig. 4g ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.